SG11201510678TA - Bromodomain inhibitors - Google Patents

Bromodomain inhibitors

Info

Publication number
SG11201510678TA
SG11201510678TA SG11201510678TA SG11201510678TA SG11201510678TA SG 11201510678T A SG11201510678T A SG 11201510678TA SG 11201510678T A SG11201510678T A SG 11201510678TA SG 11201510678T A SG11201510678T A SG 11201510678TA SG 11201510678T A SG11201510678T A SG 11201510678TA
Authority
SG
Singapore
Prior art keywords
bromodomain inhibitors
bromodomain
inhibitors
Prior art date
Application number
SG11201510678TA
Inventor
Le Wang
Yujia Dai
James HOLMS
Dachun Liu
William Mcclellan
Keith MCDANIEL
Lisa Hasvold
Steven D Fidanze
George SHEPPARD
Jasmina Marjanovic
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361840559P priority Critical
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority to PCT/CN2014/077395 priority patent/WO2014206150A1/en
Publication of SG11201510678TA publication Critical patent/SG11201510678TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
SG11201510678TA 2013-06-28 2014-05-13 Bromodomain inhibitors SG11201510678TA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201361840559P true 2013-06-28 2013-06-28
PCT/CN2014/077395 WO2014206150A1 (en) 2013-06-28 2014-05-13 Bromodomain inhibitors

Publications (1)

Publication Number Publication Date
SG11201510678TA true SG11201510678TA (en) 2016-01-28

Family

ID=52140993

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201510678TA SG11201510678TA (en) 2013-06-28 2014-05-13 Bromodomain inhibitors
SG11201510677VA SG11201510677VA (en) 2013-06-28 2014-06-27 Bromodomain inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201510677VA SG11201510677VA (en) 2013-06-28 2014-06-27 Bromodomain inhibitors

Country Status (23)

Country Link
US (3) US10131657B2 (en)
EP (2) EP3013828A4 (en)
JP (2) JP2016525503A (en)
KR (2) KR20160027062A (en)
CN (2) CN105518007A (en)
AR (1) AR096757A1 (en)
AU (2) AU2014303193A1 (en)
BR (2) BR112015032710A2 (en)
CA (2) CA2916542A1 (en)
CL (1) CL2015003731A1 (en)
CR (1) CR20160035A (en)
DO (2) DOP2015000305A (en)
HK (4) HK1223363A1 (en)
IL (2) IL243372D0 (en)
MX (2) MX2015017963A (en)
NZ (1) NZ631062A (en)
PE (2) PE20160540A1 (en)
PH (2) PH12015502852A1 (en)
RU (2) RU2016102647A3 (en)
SG (2) SG11201510678TA (en)
TW (1) TW201536780A (en)
UY (1) UY35633A (en)
WO (2) WO2014206150A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227985B2 (en) 2013-03-15 2016-01-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CN105518007A (en) * 2013-06-28 2016-04-20 艾伯维公司 Bromodomain inhibitors
CA2917319A1 (en) 2013-07-08 2015-01-15 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CN108558889A (en) 2013-10-18 2018-09-21 赛尔基因昆蒂赛尔研究公司 Bu Luomo structural domain inhibitor
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3134403B1 (en) 2014-04-23 2020-02-12 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
JP6599979B2 (en) 2014-09-15 2019-10-30 インサイト・コーポレイションIncyte Corporation Tricyclic heterocyclic compounds for use as BET protein inhibitors
JP2017533248A (en) 2014-11-10 2017-11-09 ジェネンテック, インコーポレイテッド Substituted pyrrolopyridines as inhibitors of bromodomains
CN107108613B (en) 2014-11-10 2020-02-25 基因泰克公司 Bromodomain inhibitors and uses thereof
CN107108614A (en) 2014-11-10 2017-08-29 基因泰克公司 It is used as the substituted pyrrolopyridine of Bu Luomo domain inhibitor
CN107531692A (en) 2015-01-29 2018-01-02 基因泰克公司 Therapeutic compounds and application thereof
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US20190345153A1 (en) * 2016-04-15 2019-11-14 Abbvie Inc. Bromodomain Inhibitors
CN105924842A (en) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 Power cable improved in mechanical properties
CN105924671A (en) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 Toughening agent for power cable
CN105924841A (en) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 Preparation method of power cable improved in mechanical properties
PE20190623A1 (en) 2016-06-20 2019-04-26 Incyte Corp crystalline solid forms of an inhibitor beit
TW201825490A (en) * 2017-01-11 2018-07-16 大陸商江蘇豪森藥業集團有限公司 Pyrrolo[2,3-c]pyridine derivatives, preparation methods and pharmaceutical uses thereof
CN109384784A (en) * 2017-08-10 2019-02-26 浙江海正药业股份有限公司 Sulfonic acid amide derivatives, preparation method and its purposes in medicine
KR102026243B1 (en) * 2018-01-19 2019-09-27 연세대학교 산학협력단 Pharmaceutical composition for treating leukemia
CN110305123A (en) * 2018-03-27 2019-10-08 成都海创药业有限公司 A kind of compound containing adamantane and its purposes in treating cancer
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
CN110776508A (en) * 2018-07-27 2020-02-11 成都海创药业有限公司 BRD4 inhibitor and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (en) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JPH08337583A (en) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd Heterocyclic compound and its production
US6271380B1 (en) * 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
JP5159305B2 (en) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 Thienotriazolodiazepine compounds and their use as pharmaceuticals
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011143669A2 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc Compositions and methods for treating neoplasia, inflammatory disease and other disorders
CN103119160B (en) 2010-05-14 2016-06-01 达那-法伯癌症研究所 For regulating compositions and the method for metabolism
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN105518007A (en) * 2013-06-28 2016-04-20 艾伯维公司 Bromodomain inhibitors

Also Published As

Publication number Publication date
EP3013828A4 (en) 2016-11-23
WO2014206345A1 (en) 2014-12-31
EP3013828A1 (en) 2016-05-04
US9957263B2 (en) 2018-05-01
CA2916542A1 (en) 2014-12-31
RU2016102647A (en) 2017-08-01
PE20160540A1 (en) 2016-06-11
EP3013827A4 (en) 2016-11-23
HK1224296A1 (en) 2017-08-18
KR20160027062A (en) 2016-03-09
US20160272630A1 (en) 2016-09-22
JP2016523271A (en) 2016-08-08
RU2016102647A3 (en) 2018-03-30
MX2015017964A (en) 2017-02-15
HK1223364A1 (en) 2017-07-28
IL243371D0 (en) 2016-02-29
MX2015017963A (en) 2016-11-10
HK1224297A1 (en) 2017-08-18
BR112015032693A2 (en) 2017-07-25
BR112015032710A2 (en) 2017-07-25
CN105518007A (en) 2016-04-20
TW201536780A (en) 2015-10-01
US20160185769A1 (en) 2016-06-30
IL243372D0 (en) 2016-02-29
RU2016102648A (en) 2017-08-02
CA2916744A1 (en) 2014-12-31
EP3013827A1 (en) 2016-05-04
CN105531273A (en) 2016-04-27
US20190084981A1 (en) 2019-03-21
AR096757A1 (en) 2016-02-03
AU2014301818A1 (en) 2016-01-28
PH12015502852A1 (en) 2016-03-21
US10131657B2 (en) 2018-11-20
AU2014303193A1 (en) 2016-01-28
HK1223363A1 (en) 2017-07-28
PE20160200A1 (en) 2016-05-21
UY35633A (en) 2014-10-31
DOP2015000308A (en) 2016-03-15
CR20160035A (en) 2016-04-22
JP2016525503A (en) 2016-08-25
PH12016500024A1 (en) 2016-03-28
DOP2015000305A (en) 2016-01-31
SG11201510677VA (en) 2016-01-28
RU2016102648A3 (en) 2018-04-26
CL2015003731A1 (en) 2016-07-29
NZ631062A (en) 2018-03-23
WO2014206150A1 (en) 2014-12-31
KR20160027107A (en) 2016-03-09

Similar Documents

Publication Publication Date Title
HK1222646A1 (en) Benzimidazole derivatives as bromodomain inhibitors
HRP20170750T1 (en) Benzimidazolone derivatives as bromodomain inhibitors
ZA201800854B (en) Novel bicyclic bromodomain inhibitors
HK1218547A1 (en) Novel quinazolinones as bromodomain inhibitors
EP2970340A4 (en) Beta-lactamase inhibitors
EP2943204A4 (en) Beta-lactamase inhibitors
DK3354246T3 (en) Udstyrsmonteringssystem
EP2968282A4 (en) Histone dementhylase inhibitors
GB201311001D0 (en) Lucabella
RU2015137103A (en) Furopyridines as Bromodomain Inhibitors
HK1218909A1 (en) Dihydro pyrrolopyridinone bromodomain inhibitors
RU2015143192A (en) Tetracyclic bromodomain inhibitors
HRP20171151T1 (en) Cdc7 inhibitors
HK1222846A1 (en) Substituted benzylpyrazoles
RU2016102591A (en) Crystalline bromodomain inhibitors
HK1221717A1 (en) Substituted benzylpyrazoles
HK1224296A1 (en) Bromodomain inhibitors
EP3057586A4 (en) Bromodomain inhibitors
PL2953956T3 (en) Heteropolyoxometalates
SG11201604612QA (en) Magnetic omni-wheel
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
IL239827D0 (en) Methoblic triphosphatase inhibitors
HRP20180382T1 (en) Protein kinase inhibitors
HRP20171097T1 (en) Neprilysin inhibitors
HRP20181775T1 (en) Arylquinazolines